Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2005-09-20
2005-09-20
Spector, Lorraine (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C435S069500, C424S085100
Reexamination Certificate
active
06946548
ABSTRACT:
The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.
REFERENCES:
patent: 4810643 (1989-03-01), Souza
patent: 4904584 (1990-02-01), Shaw
patent: 5214132 (1993-05-01), Kuga et al.
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5581476 (1996-12-01), Osslund
patent: 5849883 (1998-12-01), Boone et al.
patent: 6555660 (2003-04-01), Nissen et al.
patent: A-76380/91 (1991-11-01), None
patent: A-10948/92 (1992-08-01), None
patent: 0 243 153 (1987-10-01), None
patent: 0 256 843 (1988-02-01), None
patent: 0 272703 (1988-06-01), None
patent: 0 335 423 (1989-10-01), None
patent: 0 456 200 (1991-05-01), None
patent: 0 459 630 (1991-12-01), None
patent: 2 213 821 (1989-08-01), None
patent: WO 90/12874 (1990-11-01), None
Hacein-Bey, S., et al., “Optimization of retroviral gene transfer protocol to maintain the lympoid potential of progenitor cells”, Human Gene Therapy 12:291-301, Feb. 10, 2001. (Provided by applicants, no copy enclosed).
N.Y. Ip, “The neurotrophins and neuropoietic cytokines: two families of growth factors acting on neural and hematopoietic cells”, Ann. NY Acad. Sci. 840:97-106, May 1, 1998. (Provided by applicants, no copy enclosed).
Lauffenburger et al., “Scratching the (cell) surface: cytokine engineering for improved ligand/receptor trafficking dynamics”,Chem Biol5:R257-R263, 1998.
French and Lauffenburger, “Controlling Receptor/Ligand Trafficking: Effects of Cellular and Molecular Properties on Endosomal Sorting”,Ann Biomed Eng25:690-707, 1997.
Vecchiarelli et al., “Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS”,J Infect Dis171: 1448-1454, 1995.
Fukunaga et al., “Growth and Differentiation Signals Mediated by Different Regions in the Cytoplasmic Domain of Granulocyte Colony-Stimulating Factor Receptor”,Cell74:1079-1087, 1993.
Welte et al., “Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor”,Proc Natl Acad Sci USA82:1526-1530, 1985.
Souza et al., “Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells”,Science232:61-65, 1986.
Gabrilove, “Introduction and Overview of Hematopoietic Growth Factors”,Sem Hematol26(2):1-14, 1989.
Wendel et al., “Granulocyte Colony-Stimulating Factor Treatment Protects Rodents Against Lipopolysaccharide-Induced Toxicity Via Suppression of Systemic Tumor Necrosis Factor”,J Immunol149:918-924, 1992.
Horan et al., “Dimerization of the Extracellular Domain of Granulocyte-Colony Stimulating Factor Receptor by Ligand Binding: A Monovalent Ligand Induces 2:2 Complexes”,Biochemistry35:4886-4896, 1996.
Horan et al., “Dimerization of Granulocyte-Colony Stimulating Factor Receptor: The Ig Plus CRH Construct of Granulocyte-Colony Stimulating Factor Receptor Forms a 2:2 Complex with a Ligand”,J Biochem121:370-375, 1997.
Fukunaga et al., “Functional domains of the granulocyte colony-stimulating factor receptor”,EMBO J10:2855-2865, 1991.
Aritomi et al., Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme,Nature401:713-717, 1999.
Jones et al., “Growth factors in haemopoiesis”,Bailliere's Clin Hematol2(1 ):83-111, 1989.
Nagata et al., “The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor”,EMBO5:575-581, 1986.
Moore et al., “Synergy of interleukin 1 and granulocyte colony-stimulating factor: In Vivo stimulation of stem cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice”,Proc Natl Acad Sci USA84:7134-7138, 1987.
Diflo et al., “ASSLD Abstract of Papers”,Hepatology16:PA278, 1992.
Wright et al., “Abstracts of Papers Submitted to the American Association for the Study of Liver Diseases”,Hepatology14:PA48, 1991.
Lachaux et al., “Treatment with lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) and orthotopic liver transplantation for glycogen storage disease type Ib”,J Ped123:1005-1008, 1993.
Colquehoun et al., “Reversal of Neutropenia with Granulocyte Colony-Stimulating Factor Without Precipitating Liver Allograft Rejection”,Transplantation56:755-758, 1993.
Kuga et al., “Mutagenesis of human granulocyte colony stimulating factor”,Biochem Biophys Res Comm159:103-111, 1989.
Lu et al., Disulfide and Secondary Structures of Recombinant Human Granulocyte Colony Stimulating Factor,Arch Biochem Biophys268:81-92. 1989.
Okabe et al., “In Vitro and In Vivo Hematopoietic Effect of Mutant Human Granulocyte Colony-Stimulating Factor”,Blood75(9):1788-1793, 1990.
Yang and Honig, “On the pH Dependence of Protein Stability”,J Mol Biol231:459-474, 1993.
Tanokura, “H-NMR Study on the Tautomerism of the Imidazole Ring of Histidine Residues: I. Microscopic ρK Values and Molar Ratios of Tautomers in Histidine-Containing Peptides”,Biochim Biophys Acta742:576-585, 1982.
Kangas and Tidor, “Optimizing electrostatic affinity in ligand-receptor binding: Theory, computation, and ligand properties”,J Chem Phys109:7522-7545, 1998.
Kuwubara et al., “Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats”,Amer J Physiol Endocrinol Metabol32:EI-E9, 1995.
Wiley et al., “The Endocytotic Rate Constant: A Cellular Parameter for Quantitating Receptor-Mediated Endocytosis”,J Biol Chem257:4222-4229, 1982.
Aritomi et al., “Purification, crystallization and preliminary X-ray analysis of a complex between granulocyte colony-stimulating factor and its receptor”,Acta Crystallogr D Biol Crystallogr56:751-753, 2000.
Berman et al., “The Protein Data Bank”,Nucl Acids Res28:235-242, 2000.
Brooks et al., “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamic Calculations”,J Comput Chem4:187-217, 1983.
Brunger and Karplus, “Polar Hydrogen Positions in Proteins: Empirical Energy Placement and Neutron Diffraction Comparison”,Proteins4:148-156, 1988.
Dunbrack and Karplus, “Backbone-dependent Rotamer Library for Proteins: Application to Side-chain Prediction”,J Mol Biol230:543-574, 1993.
Gilson and Honig, “Calculation of electrostatic potentials in an enzyme active site”,Nature330:84-86, 1987.
Sitkoff et al., “Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models”,J Phys Chem98:1978-1988, 1994.
Desmet et al., “The dead-end elimination theorem and its use in protein side-chain positioning”,Nature356:539-542, 1992.
Goldstein, “Efficient Rotamer Elimination Applied to Protein Side-Chains and Related Spin Glasses”,Biophys J66:1335-1340, 1994.
Hendsch and Tidor, “Electrostatic interactions in the GCN4 leucine zipper: Substantial contributions arise from intramolecular interactions enhanced on binding”,Protein Sci8:1381-1392, 1999.
Gilson et al., “Calculating the Electrostatic Potential of Molecules in Solution: Method and Error Assessment”,J Comput Chem9:327-335, 1988.
Sharp and Honig, “Electrostatic Interaction in Macromolecules: Theory and Applications”,Annu Rev Biophys Chem19:301-332, 1990.
Leach and Lemon, “Exploring the Conformational Space of Protein Side Chains Using Dead-E
Lauffenburger Douglas A.
Sarkar Casim A.
Tidor Bruce
Marshall & Gerstein & Borun LLP
Massachusetts Institute of Technology
Spector Lorraine
LandOfFree
G-CSF analog compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with G-CSF analog compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and G-CSF analog compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3441392